Thermo Fisher Scientific Introduces Software, Instruments, and Consumables - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Thermo Fisher Scientific Introduces Software, Instruments, and Consumables


Thermo Fisher Scientific launched new software, instruments, consumables, and services for analytical applications at Pittcon 2013.

Thermo Scientific Chromeleon ver. 7.2 chromatography data systems software, supports Thermo Scientific mass spectrometers and allows instruments to be integrated on enterprise-wide networks.

The Thermo Scientific Nicolet iS50 spectrometer can be upgraded from a FT-IR system to multi-range device capable of ATR, Raman, and NIR analysis without manually changing components.

The Thermo Scientific Dionex UltiMate 3000 Biocompatible Rapid Separation (BioRS) system, combines ultra-high performance liquid chromatography (UHPLC) with a corrosion-resistant flow path that can withstand high salt or extreme pH conditions.

The Thermo Scientific Dionex GlycanPac AXH-1 HPLC column allows for better analysis of glycans.

The iCAP 7000 family of inductively coupled plasma-optical emission spectrometers (ICP-OES) feature a high-resolution charged injection device (CID) imager.

The Thermo Scientific PicoSpin-45 spectrometer is a miniature NMR spectrometer designed for applied analysis in laboratories of any size.

Unity Lab SmartCapture Asset Utilization Monitoring provides automated support, service and maintenance, regardless of the instrument manufacturer.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here